YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $27.5, a high estimate of $36.00 ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) ...

Liquidia Corporation ( NASDAQ: LQDA) said on Friday that the U.S. FDA has approved Yutrepia inhalation powder, a prostacyclin ...

Dr. Roger Jeffs, CEO, Liquidia said: “We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales ...

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary ...

Liquidia (NASDAQ:LQDA – Get Free Report) had its target price boosted by equities research analysts at Scotiabank from $36.00 to $37.00 in a report issued on Wednesday,Benzinga reports.